Loading
No insider purchase over the last 90 days. The latest was filed 16 Mar 2026.
Ultralife Corp: what insiders have been doing
Headquartered in Newark, United States, Ultralife Corp belongs to the Industry sector and traces its origins to 1990. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Ultralife Corp logged 7 filings by 4 insiders.
The flow runs one way only: 4 insiders bought (7 purchases totalling €482k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €231k, bought by Whitmore Bradford T and made public on 21 November 2025. Among those who bought: 3 senior executives and 1 chief executive.
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 7 filings here. The full history, which starts in 2021, counts 49 purchases against no sales.
The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (16 March 2026) now reads 216 days. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Tennant Co and Butler National Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
57
Thresholds
n/a
Buy Volume
€2M
49 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBradford T. Whitmore7 buys
Michael Edward Manna4 buys
W. Shaw Robert3 buys
Janie Goddard2 buys
Thomas Louis Saeli1 buy
Since the insiders bought
- -4.8%Entry US$6.93 · Close at T+90 US$6.60
- -4.8%Entry US$6.93 · Close at T+90 US$6.60
- +21.1%Entry US$5.79 · Close at T+90 US$7.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,823 of 24,148 companies
35.6
score / 100
Value46
Quality25
FCF yld6.8%
Earn yld-5.7%
EV/EBITDA·
ROE-4.9%
Gross mgn24%
Net mgn-3.1%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.26
Analyst consensus
Income statement
RevenueUS$191.2M
Gross profitUS$46M24% margin
EBITDAUS$1.1M1% margin
Net income-US$5.9M-3.5% margin
Valuation
P/Book0.8x
Beta0.78
Balance sheet & cash
Market capUS$104.3M
Total debtUS$49.7M
Free Cash FlowUS$7.1M
Debt / Equity36%
Profitability & ownership
ROE-4.9%
ROA2.1%
% insiders3.2%
% institutions73.5%
Last declaration on 16 March 2026
Declarations57 total
1,800 shares@ US$6.015.7% of flowUltralife Common Stock; $.10 par valueSEC:0001437749-26-008418:0
Canonical exit: 10 Jun 2026 (T+90)
33,741 shares@ US$5.96630.18% mcap8.7% of flowCommon StockSEC:0000933430-26-000002:0
Canonical exit: 10 Jun 2026 (T+90)
9,530 shares@ US$5.62570.048% mcap2.3% of flowCommon StockSEC:0000933430-25-000011:0
Canonical exit: 12 Mar 2026 (T+90)
1,739 shares@ US$5.7518.0% of flowCommon Stock; $.10 par valueSEC:0001437749-25-037844:0
Canonical exit: 15 Mar 2026 (T+90)
1,750 shares@ US$5.6710.8% of flowCommon Stock; $.10 par valueSEC:0001437749-25-036397:0
Canonical exit: 22 Feb 2026 (T+90)
53,900 shares@ US$4.970611.5% of flowCommon StockSEC:0000933430-25-000010:0
Canonical exit: 17 Feb 2026 (T+90)
1,000 shares@ US$4.9432.6% of flowCommon Stock; $.10 par valueSEC:0001437749-25-035716:0
Canonical exit: 17 Feb 2026 (T+90)
15,898 shares@ US$6.56480.094% mcap4.5% of flowCommon StockSEC:0000933430-25-000009:0
Canonical exit: 17 Nov 2025 (T+90)
1,548 shares@ US$7.6821.7% of flowCommon Stock; $.10 par valueSEC:0001437749-25-020305:0
Canonical exit: 11 Sept 2025 (T+90)
10,000 shares@ US$7.63923.3% of flowCommon StockSEC:0000933430-25-000006:0
Canonical exit: 11 Sept 2025 (T+90)
11,980 shares@ US$5.40722.9% of flowCommon StockSEC:0000933430-25-000003:0
Canonical exit: 21 Aug 2025 (T+90)
8,957 shares@ US$5.39832.2% of flowCommon StockSEC:0000933430-25-000002:0
Canonical exit: 11 Aug 2025 (T+90)
4,000 shares@ US$5.4924.7% of flowCommon Stock; $.10 par valueSEC:0001437749-25-016753:0
Canonical exit: 12 Aug 2025 (T+90)
5,000 shares@ US$5.4422.0% of flowCommon Stock; $.10 par valueSEC:0001437749-25-016888:0
Canonical exit: 12 Aug 2025 (T+90)
3,000 shares@ US$5.298.7% of flowCommon Stock; $.10 par valueSEC:0001437749-25-016413:0
Canonical exit: 11 Aug 2025 (T+90)
1,500 shares@ US$7.2456.3% of flowCommon Stock; $.10 par valueSEC:0001437749-24-035916:0
Canonical exit: 19 Feb 2025 (T+90)
2,500 shares@ US$7.9123.3% of flowCommon Stock; $.10 par valueSEC:0001437749-24-034590:0
Canonical exit: 10 Feb 2025 (T+90)
1,397 shares@ US$10.9129.6% of flowCommon Stock; $.10 par valueSEC:0001437749-24-019604:0
Canonical exit: 5 Sept 2024 (T+90)
7,179 shares@ US$5.707550.3% of flowCommon Stock; $.10 par valueSEC:0001437749-24-012544:0
1,000 shares@ US$8.604.8% of flowULBI Common Stock; $.10 par valueSEC:0001437749-24-007608:0
Canonical exit: 11 Jun 2024 (T+90)
5,059 shares@ US$5.305714.8% of flowULBI Common Stock; $.10 par valueSEC:0001437749-23-035549:0
8,877 shares@ US$6.82712.8% of flowCommon StockSEC:0000933430-23-000017:0
Canonical exit: 5 Mar 2024 (T+90)
3,200 shares@ US$7.11961.0% of flowCommon StockSEC:0000933430-23-000016:0
Canonical exit: 25 Feb 2024 (T+90)
500 shares@ US$7.432.1% of flowCommon Stock; $.10 par valueSEC:0001437749-23-031457:0
Canonical exit: 8 Feb 2024 (T+90)
10,171 shares@ US$7.03623.4% of flowCommon StockSEC:0000933430-23-000014:0
Canonical exit: 28 Jan 2024 (T+90)
25 of 57 declarations
About Ultralife Corp
Ultralife Corp. (ticker: ULBI) is a U.S.-based industrial company listed on the NASDAQ Global Market in the United States. The company develops and manufactures mission-critical battery and RF power and communications solutions for government, defense, industrial, and commercial customers. Its corporate headquarters is in Newark, New York, where it also maintains a major operating and manufacturing footprint. The company traces its modern origins to 1991, when it came public out of the battery activities associated with Kodak’s Ultra Technologies division. Since then, Ultralife has expanded through a mix of internal development and targeted acquisitions.
Ultralife reports its operations in two core segments: Battery & Energy Products and Communications Systems. Battery & Energy Products includes lithium 9-volt, cylindrical, thin-cell, and other non-rechargeable batteries, as well as rechargeable batteries, uninterruptible power supplies, charging systems, and related accessories. Communications Systems covers RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed and vehicle applications, and systems engineering services. This product mix places Ultralife in a specialized niche rather than in commodity batteries, with revenues tied to technical applications where reliability, performance, and custom engineering matter more than price alone.
Read moreShow less
From a competitive standpoint, the company positions itself as a mission-critical solutions provider with strong engineering capabilities, application-specific customization, and a diversified portfolio across power and communications end markets. It serves customers across North America, Europe, and Asia, supported by development and manufacturing resources in multiple regions. The company also markets products under several brands, including Ultralife, Accutronics, Electrochem, Excell, and SWE.
Recent strategic developments have been important. In October 2024, Ultralife completed its acquisition of Electrochem Solutions, strengthening its battery manufacturing capabilities and broadening its exposure to energy, military, and industrial applications. In its 2025 annual report, management said it realigned several thionyl chloride/oil & gas operations into a single business within Battery & Energy Products to optimize synergies and deepen customer engagement. The company also reported backlog of about $110 million at the end of 2025, up sequentially, which points to improved near-term visibility and stronger order flow.
For investors, ULBI remains a niche industrial name with meaningful exposure to defense, specialty energy storage, and communication systems. The business is highly dependent on contract timing, product mix, and execution, but its acquisition-led expansion and backlog growth indicate a company seeking to build scale and improve profitability over time.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
